Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

SINGAPORE, Sept. 12, 2023. On September 9th, 2023, Biosyngen Pte Ltd  announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials